Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival.

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and biofuels company, announced today that Aemetis Chairman and CEO ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

DelveInsight’s, “Metastatic Urothelial Carcinoma Pipeline Insight, 2025” report provides comprehensive insights about 40+ ...

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,” report provides comprehensive insights about 120+ ...